Kringle Pharma, Inc.

As of March 31, 2026, Kringle Pharma, Inc. carries a market capitalization of 3.01B, placing it among publicly traded companies globally. Its enterprise value stands at 1.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kringle Pharma, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of March 31, 2026, Kringle Pharma, Inc. has 7.40M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Kringle Pharma, Inc. maintains a current ratio of 4.79, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Kringle Pharma, Inc.'s stock has gained approximately 32.32% over the past 52 weeks. The 50-day moving average sits at 487.42, while the 200-day moving average is 412.93.

These figures are as of March 31, 2026. Total book value stands at 947.88M, with working capital of 1.55B providing operational flexibility.